<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101447</url>
  </required_header>
  <id_info>
    <org_study_id>PRUNE</org_study_id>
    <nct_id>NCT05101447</nct_id>
  </id_info>
  <brief_title>Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis</brief_title>
  <acronym>PRUNE</acronym>
  <official_title>Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meta-analyses in adults suggest equivalence of clinical efficacy of intravenous&#xD;
      cyclophosphamide and mycophenolate mofetil when dosed based on patient weight or&#xD;
      body-surface-area (MMFBSA), as is the current standard for the treatment of proliferative&#xD;
      lupus nephritis (LN) treatments in the U.S. Pharmacokinetically-guided precision dosing of&#xD;
      MMF (MMFPK) may offer a beneficial modification of the current standard treatment in that&#xD;
      MMKPK promises over 30% higher LN response rates than MMFBSA. The objective of the proposed&#xD;
      randomized, controlled study is to compare the efficacy and safety of&#xD;
      pharmacokinetically-guided precision dosing of MMF (MMFPK) with conventional dosing regimens&#xD;
      of MMF (MMFBSA) among children with proliferative LN.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal remission</measure>
    <time_frame>26 week</time_frame>
    <description>defined as at least PRR (CRR or PRR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Renal Remission</measure>
    <time_frame>week 26</time_frame>
    <description>CRR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>MMF PK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MMF BSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care [MMFBSA: 600 mg/m2/dose; max: 3 gram/day] or pharmacokinetically-driven precision dosing [MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg*h/L].</description>
    <arm_group_label>MMF BSA</arm_group_label>
    <arm_group_label>MMF PK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        New diagnosis with proliferative LN based on kidney biopsy done within 4 weeks of&#xD;
        enrollment Diagnosis with childhood-onset SLE (cSLE) as per the ACR criteria95, 96 Age 8 -&#xD;
        17 years at the time of enrollment96 Tolerates oral MMF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Perceived or stated inability to adhere to study protocol, Lack of use of highly effective&#xD;
        birth control method. Presence of cSLE features that a-priori suggest that the patient&#xD;
        benefits from other therapy than that suggested by the study protocol, History of&#xD;
        significant kidney disease prior to the diagnosis with cSLE, Need for renal replacement&#xD;
        therapy at the time of enrolment, Concurrent therapy with CYC or rituximab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lupus Team</last_name>
    <phone>5138032118</phone>
    <email>lupusteam_1@cchmc.org</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Hermine Brunner, MD</investigator_full_name>
    <investigator_title>Director, Division of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

